The FDA hit Las Vegas compounder ACRx Specialty Pharmacy for poor aseptic practices and other GMP failures observed during an inspection last year.

The FDA has released final guidance explaining when drug or biologic sponsors must submit pediatric study plans.

The FDA has updated its Purple Book to include all licensed biological products overseen by the Centers for Biologics Evaluation and Research (CBER) and Drug Evaluation and Research (CDER).